Drugs / Humiome(R) Post LB
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT07366931 Comparator | Jan → Jul 2026 overdue | — | Liverpool John Moores University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Humiome(R) Post LB | “Participants allocated to this arm will receive the investigational product (Humiome(R) Post LB), to be ingested daily for three consecutive menstrual cycles.” NCT07366931 ↗ |
| Route | Oral | “to be ingested daily for three consecutive menstrual cycles” NCT07366931 ↗ |